Peer-reviewed veterinary case report
Low-dose half-body radiation plus chemo for dog lymphoma treatment
By Lurie, D M et al.·Published in Journal of veterinary internal medicine·2009·Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
- Species:
- dog
Plain-English summary
A group of 38 dogs with multicentric lymphoma (a type of cancer affecting the lymph nodes) received a combination of low-dose radiation therapy and chemotherapy to treat their condition. The treatment involved a specific schedule that allowed for a two-week break between radiation sessions. Many dogs responded well, with the average time before the cancer returned being about 410 days, and some dogs living for nearly two years or more after starting treatment. This approach showed promising results, suggesting it could be an effective option for dogs diagnosed with lymphoma.
People also search for: dog lymphoma treatment · canine cancer survival rates · chemotherapy for dogs with lymphoma
Abstract
BACKGROUND: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. HYPOTHESIS: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. ANIMALS: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. METHODS: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. RESULTS: The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. CONCLUSIONS AND CLINICAL RELEVANCE: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19627472/